FBP1 and BRAF

Data Source:
BioGRID (two hybrid)

		FBP1	BRAF
Description		fructose-bisphosphatase 1	B-Raf proto-oncogene, serine/threonine kinase
Image
GO Annotations	Cellular Component	Nucleus Cytoplasm Cytosol Extracellular Exosome	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle
	Molecular Function	RNA Polymerase II Transcription Factor Binding Protein Binding AMP Binding Fructose 1,6-bisphosphate 1-phosphatase Activity Identical Protein Binding Metal Ion Binding Monosaccharide Binding	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity
	Biological Process	Negative Regulation Of Transcription By RNA Polymerase II Sucrose Biosynthetic Process Fructose Metabolic Process Fructose 6-phosphate Metabolic Process Gluconeogenesis Regulation Of Gluconeogenesis Dephosphorylation Negative Regulation Of Cell Growth Fructose 1,6-bisphosphate Metabolic Process Cellular Response To Drug Negative Regulation Of Glycolytic Process Negative Regulation Of Ras Protein Signal Transduction Cellular Response To Magnesium Ion	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane
Pathways		Gluconeogenesis	Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants
Drugs		Adenosine phosphate 2,5-Anhydroglucitol-1,6-Biphosphate {4-[3-(6,7-Diethoxy-Quinazolin-4-Ylamino)-Phenyl]-Thiazol-2-Yl}-Methanol Mdl-29951 Fructose-6-phosphate MB-07803 Managlinat dialanetil N-[7-(3-AMINOPHENYL)-5-METHOXY-1,3-BENZOXAZOL-2-YL]-2,5-DICHLOROBENZENESULFONAMIDE 2,5-DICHLORO-N-(5-CHLORO-1,3-BENZOXAZOL-2-YL)BENZENESULFONAMIDE 2,5-DICHLORO-N-[5-METHOXY-7-(6-METHOXYPYRIDIN-3-YL)-1,3-BENZOXAZOL-2-YL]BENZENESULFONAMIDE 4-AMINO-N-[(2-SULFANYLETHYL)CARBAMOYL]BENZENESULFONAMIDE	Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib
Diseases		Fructose-1,6-bisphosphatase deficiency	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		Cerebrospinal fluid t-tau:AB1-42 ratio ( 28641921) Colorectal or endometrial cancer ( 26621817) Obesity-related traits ( 23251661)	anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)
Interacting Genes		38 interacting genes: ACTN1 APC ASCC2 ASL ATP5MF AXIN2 BCL10 BCL2L1 BIN1 BMPR1A BRAF BUB1 CSNK1E CTNNA1 DCC DYNC1I1 ERBB2 FBP2 FBXW7 FLCN FXR2 HDAC6 HSPA8 KLRC2 LNX1 MLH3 MSH2 PCNX4 POT1 PRKN PTK2 PTPRJ RB1 RNF183 STK11 TERF1 TLR2 TRIM28	46 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510
Entrez ID		2203	673
HPRD ID		01973	01264
Ensembl ID		ENSG00000165140	ENSG00000157764
Uniprot IDs		P09467 Q2TU34	P15056
PDB IDs		1FTA 2FHY 2FIE 2FIX 2JJK 2VT5 2WBB 2WBD 2Y5K 2Y5L 3A29 3KBZ 3KC0 3KC1 4MJO 5LDZ 5PZQ 5PZR 5PZS 5PZT 5PZU 5PZV 5PZW 5PZX 5PZY 5PZZ 5Q00 5Q01 5Q02 5Q03 5Q04 5Q05 5Q06 5Q07 5Q08 5Q09 5Q0A 5Q0B 5ZWK 6LS5 6LW2 7CVN	1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6XAG
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?